ET AL. V. JANSSEN BIOTECH, INC., ET AL., CASE NO. 19-CV-14146 (D.N.J.)
LGN represents end payor plaintiffs who allege an unlawful scheme by defendants to prolong their monopoly in the market for Zytiga® (abiraterone acetate), a drug used to treat patients with prostate cancer. LGN seeks to recover damages for a proposed class of end payors who purchased Zytiga® indirectly from defendants beginning December 13, 2016 through the present. The case is pending in the United States District Court for the District of New Jersey before the Honorable James B. Clark.